ReviewInternational journal of molecular sciences2016
Prodrug Strategies for Paclitaxel.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer.Frontiers in pharmacology · 2019Pooled it
- Targeted paclitaxel delivery in ovarian cancer via AP1-functionalized elastin-like polypeptide nanocarriers: development and characterization.BMC cancer · 2026Article
- Self-assembly of paclitaxel derivative and fructose as a potent inducer of immunogenic cell death to enhance cancer immunotherapy.Materials today. Bio · 2025Article
- Tumor-specific biochemical nanoconversion of self-assembled peptide-conjugated paclitaxel-docetaxel-based nanoparticles.Nano convergence · 2025Article
- β-d-Ribofuranose as a Core with a Phosphodiester Moiety as the Enzyme Recognition Site for Codrug Development.Organic letters · 2024Article
- Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy.Acta pharmaceutica Sinica. B · 2024Review
- Design and Synthesis of Dimethylaminomethyl-Substituted Curcumin Derivatives: Potent Anti-Inflammatory, Anti-Oxidant, and Radioprotection Activity, Improved Aqueous Solubility Compared with Curcumin.Molecules (Basel, Switzerland) · 2024Article
- Biomarkers in Ovarian Cancer: Towards Personalized Medicine.Proteomes · 2024Review
- Strategies for the development of stimuli-responsive small molecule prodrugs for cancer treatment.Frontiers in pharmacology · 2024Review
- iRGD-Guided Silica/Gold Nanoparticles for Efficient Tumor-Targeting and Enhancing Antitumor Efficacy Against Breast Cancer.International journal of nanomedicine · 2024Article
- Identification and validation of a novel anoikis-related long non-coding RNA signature for pancreatic adenocarcinoma to predict the prognosis and immune response.Journal of cancer research and clinical oncology · 2023Article
- A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy.Molecules (Basel, Switzerland) · 2023Article
- Exosomes as Novel Delivery Systems for Application in Traditional Chinese Medicine.Molecules (Basel, Switzerland) · 2022Review
- Sustained Drug Release from Smart Nanoparticles in Cancer Therapy: A Comprehensive Review.Micromachines · 2022Review
- Biopolymeric Prodrug Systems as Potential Antineoplastic Therapy.Pharmaceutics · 2022Review
- Palbociclib regulates the expression of dihydrofolate reductase and the cell cycle to inhibit t (11;14) multiple myeloma.Annals of translational medicine · 2022Article
- Glucose-Modified Zein Nanoparticles Enhance Oral Delivery of Docetaxel.Pharmaceutics · 2022Article
- Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates.International journal of molecular sciences · 2022Article
- Bioactive Keratin and Fibroin Nanoparticles: An Overview of Their Preparation Strategies.Nanomaterials (Basel, Switzerland) · 2022Review
- Synthesis and Biological Investigation of Bile Acid-Paclitaxel Hybrids.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have been developed by many research groups from all over the world. In this review, we discuss the different strategies especially prodrug strategies that are currently used to make paclitaxel more effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.